Heartseed Inc. and Novo Nordisk - in partnership since June 2021 - have announced that the first patient has been successfully dosed in a clinical study with HS-001, a cell therapy designed to ...

SY-001 is under development for the treatment of advanced solid tumors including advanced ovarian cancer and pancreatic cancer. It comprises of induced pluripotent stem cells derived macrophages which ...